Cure8 research brief
The review suggests baseline corticosteroid use may change how well some advanced UC therapies work, especially IL-23 inhibitors and S1P modulators, which could affect treatment choices and trial reporting.
Clinicians treating moderate-to-severe ulcerative colitis, researchers designing or analyzing UC trials, and patients considering or starting biologics/small molecules who are using or may use bridging corticosteroids.
The analysis included 10 randomized controlled trials and found higher rates of endoscopic improvement, symptom relief, and clinical remission during induction among patients who were CS-naïve versus those using CS at baseline.
However, the effect varied by drug class: IL-23 inhibitors showed consistent advantage for CS-naïve patients across several endpoints, S1P modulators showed large effect sizes for histologic–endoscopic mucosal improvement, and JAK inhibitors numerically favored CS-exposed patients though not significantly.
Short-term concomitant CS (up to 52 weeks in available data) did not clearly increase adverse events in the pooled trials. How to use this information These findings suggest baseline CS status could be an important factor to report and consider in trials and possibly in clinical decision-making, but they do not prove causation.
The authors call for prospective studies to confirm whether CS exposure meaningfully modifies drug effectiveness. Discussing steroid use and timing with your IBD clinician remains important when planning advanced therapy.
This article is a meta-analysis of randomized trials (registered in PROSPERO). Results are pooled and hypothesis-generating; the authors recommend prospective studies for confirmation. The structured content is an abstract-based summary of the published article.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Mirikizumab showed higher rates of clinical and endoscopic remission than placebo in pooled randomized trials, which could expand treatment options for people with moderate-to-severe ulcerative colitis if confirmed by...
Achieving histologic or biochemical remission in addition to clinical and endoscopic remission was associated with substantially lower relapse risk in ulcerative colitis across multiple follow-up intervals, suggesting...
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...
